Labcorp Holdings Inc. (NYSE: LH) Financial Overview and Analyst Insights

Labcorp's consensus price target is $275, indicating a positive outlook from analysts with a gradual increase from the previous year's target of $262.43. The company reported a significant increase in Q2 2025 revenue to $3.53 billion and an improved diluted EPS of $2.84. Analyst Derik de Bruin from Bank of America Securities has set a higher price target of $370 for Labcorp, reflecting confidence in the company's strategic initiatives and market position.

Labcorp Holdings Inc. (NYSE: LH) is a key player in the laboratory services industry, offering a wide range of services to clients such as doctors, hospitals, and pharmaceutical companies. The company is known for its comprehensive testing and laboratory services, which are crucial for healthcare providers and researchers. Labcorp competes with other major players in the industry, including Quest Diagnostics and BioReference Laboratories.

The stock of Labcorp has been closely analyzed by financial experts, who provide target price estimates to guide investors. Recently, the consensus price target for Labcorp was $275, reflecting a positive outlook from analysts. This target remained consistent over the last quarter, indicating sustained confidence in the company's performance and potential. A year ago, the target was $262.43, showing a gradual increase in expectations over time.

Labcorp's recent financial results support this positive sentiment. In the second quarter of 2025, the company reported a significant increase in revenue, rising to $3.53 billion from $3.22 billion in the same period of 2024. Diluted earnings per share (EPS) also improved, reaching $2.84 from $2.43. The adjusted EPS rose to $4.35 from $3.94, highlighting the company's strong financial performance.

In response to these results, Labcorp has raised its full-year guidance. The company now expects revenue growth between 7.5% and 8.6%, with the midpoint increased by 70 basis points. The adjusted EPS guidance has been adjusted to a range of $16.05 to $16.50, with the midpoint increased by $0.23. Additionally, the free cash flow projection is set between $1.13 billion and $1.28 billion, with the midpoint raised by $25 million.

Analyst Derik de Bruin from Bank of America Securities has set a price target of $370 for Labcorp, reflecting confidence in the company's strategic initiatives and market position. This target suggests a potential upside for investors, as Labcorp continues to expand its partnerships and introduce new tests in high-growth specialty areas like oncology. The company's strong track record of surpassing earnings expectations further supports this optimistic outlook.